1 / 9

Scientific Symposium

Scientific Symposium. Opening session CTOS (1 pm to 5 pm) CTOS reception (5pm to 6pm) Dinner/Consensus Discussion (6pm to 9 pm) Panel George Demetri, MD Scott Schuetze, MD, PhD Laurence Baker, DO (moderator). P=Participating NP=Not Participating *Awaiting Contract **No longer accruing.

lorin
Télécharger la présentation

Scientific Symposium

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Scientific Symposium • Opening session CTOS (1 pm to 5 pm) • CTOS reception (5pm to 6pm) • Dinner/Consensus Discussion (6pm to 9 pm) • Panel • George Demetri, MD • Scott Schuetze, MD, PhD • Laurence Baker, DO (moderator)

  2. P=Participating NP=Not Participating *Awaiting Contract **No longer accruing

  3. CR PR CR PR SD SD PD PD Month 2 Month 4

  4. PRACTICAL ADVANTAGES OF THE BAYESIAN DESIGN The hierarchical model allows data from each subtype to provide information about parameters in all other subtypes It avoids two undesirable approaches, conducting : - One trial, assuming one common parameter, ignoring the subtypes, or - Separate trials that ignore each others’ data User-friendly front ends greatly facilitate trial conduct

  5. 95% Posterior Credible Intervals by Histologic Subtype q = Pr( Response )

  6. 74 yo man with myofibroblastic sarcoma Pre-Gleevec H &. E 8 weeks on Rx cKIT

  7. 65 yo man with malignant fibrous histiocytoma Pre-Gleevec H & E 2 weeks on Rx cKIT

  8. Planned Studies • Gemcitabine/docetaxel in bone sarcomas • Imatinib neoaduvant treatment of DFSP • AMG 706 Phase II trial in sarcoma • BMS SRC inhibitor • Ziopharm active ifosphamide moiety • Uterine sarcoma adjuvant therapy

More Related